Drug
Glesatinib
Glesatinib: highest development phase Phase 2, developed by Mirati Therapeutics. 1 trial record tracked on RxWires.
- Highest phase
- Phase 2
- Developer
- Mirati Therapeutics
Trials
| Drug | Phase | Indication |
|---|---|---|
| Glesatinib NCT02954991 | Phase 2 | Carcinoma, Non-Small-Cell Lung |
Latest
No recent events.
Follow Glesatinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.